Structure-based design approach was successfully used to guide the evolution of a pyrazolo [3,4-d]pyrimidine scaffold yielding a new structural class of highly selective inhibitors of cyclin dependent kinases capable to interact with an identified part of the protein. Several compounds from this series displayed potent and selective activity against CDK2.
Introduction
The normal orderly progression through the cell division cycle is regulated by the sequential activation and deactivation of several members of the cyclin-dependent kinase (CDK) family 1 .
Virtually all cancers exhibit at least one alteration in CDK function, either through upregulation of positive effectors such as cyclins D and E, loss of negative regulators such as p16 and p27, or genetic mutations to CDK substrates 2, 3 . Consequently, there is much interest in the development of CDK inhibitors that might offer selective and tolerable treatment for cancer. Particular attention has been focused on CDK4 and CDK2 as potential targets for smallmolecule inhibition of cell cycling, although there is some controversy over which is the more important of the two. Phosphorylation of the retinoblastoma protein (pRb) by CDK4 and/or CDK6 in combination with cyclin D drives progression through the G1 phase 4 . However, inhibition of CDK4/CDK6 in cells lacking pRb does not lead to cell cycle arrest 3 , suggesting that some tumors may be insensitive to specific inhibition of CDK4. Complex formation between CDK2 and cyclin E sustains pRb phosphorylation to enable the G1-S-phase transition and activate the transcription factor E2F, leading to transcription of the genes responsible for completing DNA synthesis 4 . CDK2 then associates with cyclin A, promoting uninterrupted passage through the S phase and appropriately timed deactivation of E2F to complete this phase 3 . For the synthesis of compound (7a,b), 5-amino-4-cyano-1H-pyrazoles were refluxed with carbon disulfide in pyridine for 10 hours to give the corresponding 4,6-dithiopyrazolo [3,4-d] pyrimidine derivatives (5), which were converted to hydrazinyl derivative (6) by refluxing with hydrazine hydrate for 30 minutes. Reaction of hydrazinyl derivative with aromatic aldehydes in dimethyl formamide at room temperature gave the hydrazone derivatives (7a,b).
Finally, the hydrazinyl derivative was converted to the triazolo derivatives (8a-c) by reaction of the hydrazinyl derivative with triethyl orthoformate, acetic anhydride and carbon disulfide, also the hydrazone derivatives were converted to the triazolo derivatives by treatment with nitric acid as depicted in scheme 2. 
Biological activities
Among several classes of potential CDK2/Cyclin A inhibitors, we focused on pyrazolo [3,4-d] pyrimidine derivatives because of their known biological activities as CDK2 inhibitors, low molecular weight of the scaffold and amenability for easy structural modification. Initial hits 2,3 were selected and docked into the active site of the CDK2 receptor (PDB code 2c6i). Subsequent analysis of the docking results modifying the remaining proposed compounds by working in positions 1, 4 and 6 in the pyrazolo [3,4-d] pyrimidine moiety was directed in order to obtain maximum fit to the receptor. Finally, we carried out conformational analysis for the docked compounds to calculate the difference in energy between the best conformer and the docked one (strain energy). From the data depicted in table (1), we found that compound (3b) had the highest docking score but not the highest biological activity, this may be explained by the high strain energy (> 20 KJ/mol). The most active compound was (4a), which had IC 50 0.24 and had a high docking score and low strain energy. Also compounds 2a, 3a, 2c, 4c, 4d and 4f showed high inhibitory activity (0.27, 0.4, 0.67, 0.98, 0.77 and 0.82 µM) against CDK2 receptor and displayed both high docking score and low strain energy. Compounds 3c, 7a,b and 8e were found to be inactive although they had a high docking score that because of the very high strain energy of these compounds as compared to the most stable conformer.
Overall, the remaining of the newly synthesized compounds showed a good correlation between the biological activity and both the docking score and the strain energy. 
Conclusions
In conclusion, our results demonstrate that docking is a useful technique for designing potent and selective CDK2 inhibitors, also a simple, mild and efficient method for the synthesis of novel functionalized pyrazolo [3,4-d] pyrimidine derivatives was demonstrated. Finally, our results have showed that strain energy is an important factor to explain the difference between the docking score and biological activity.
Experimental Section
General Procedures. Melting points were determined with an electrothermal capillary melting point apparatus and are uncorrected. IR spectra (KBr disks) were recorded on a Perkin-Elmer 1430 spectrometer. 1 H-NMR and 13 C-NMR were measured with a Varian GEMINI 200 spectrometer (200 MHz for 1 H-NMR; 500MHz for 13 C-NMR). Mass spectra were recorded on a GCMS -QP 1000 EX (70EV) spectrometer. Elemental analyses were carried out at the Microanalytical Center, Cairo University. Anticancer screening of the newly synthesized compounds was carried out at the National Cancer Institute. in methanol (300 ml) was refluxed for 4 hrs. After evaporating the solvent, the residue was recrystallized from methanol to give the appropriate product (1) in good yield. 
4-(5-Amino-4-cyano-1-substituted pyrazol-3-ylamino)-N-(5-methyliso-xazol-3-yl) benzenesulfonamide derivatives (1). General procedure

4-(5-Amino-4-cyano-1H-pyrazol-3-ylamino)-N-(5-methylisoxazol-3-yl) benzenesulfonamide (1a
4-(4-
N-(5-Methylisoxazol-3-yl)-4-(4-oxo-4,5-dihydro-1-substituted pyrazolo[3,4-d]pyrimidin-3-ylamino)benzenesulfonamide derivatives (3). General procedure
A solution of 5-amino-4-cyano-1-substituted pyrazole derivatives (0.01mol) in formic acid (30 ml) was refluxed for 10 hrs. The reaction mixture was cooled, triturated with cold water and the separated solid was filtered, washed with cold water, followed by aqueous methanol, dried and recrystallized from dimethyl formamide to afford the title compound (3) . 
N-(5-Methylisoxazol-3-yl)-4-(4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino) benzenesulfonamide (3a
4-(1-(4-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d] pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (3c
4-(4-Amino-6-hydroxy(thiol)-1-substituted pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide derivatives (4). General procedure
5-amino-4-cyano-1-substituted pyrazole derivatives (0.025 mol) were heated with ureas or thioureas respectively (6g) at 180-200 0 for 20 minutes at which time the boiling liquid changes to a semi-solid mass. The cooled solid was dissolved in 2N sodium hydroxide and heated till boiling. The hot solution was acidified with glacial acetic acid and filtered. The crude product was re-precipitated twice and washed with water to give pure product (4). 
4-(4-Amino-6-hydroxy-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (4a
4-(4-Amino-6-hydroxy-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (4b
4-(4-Amino-6-hydroxy-1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1H-pyrazolo[3,4-d] pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (4c
4-(4-Hydrazinyl-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)-benzenesulfonamide (6). General procedure
To a mixture of hydrazine hydrate (5.0g, 99.9 mmol) and ethanol (5 ml), 4,6-dimercapto-1H-pyrazolo [3,4-d] pyrimidine derivative (2.6g, 5.95 mmol) was added and the mixture was heated under reflux for 15 minutes. After the reaction was completed, the precipitated crystals were collected by filtration and washed with water and ethanol to afford the hydrazinyl derivative (6 
4-(4-(2-(Arylidene)hydrazinyl)-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (7).
A mixture of the hydrazinylderivative (1.4g, 3.33 mmol) and the appropriate aldehyde (9.99 mmol) in dimethyl formamide was stirred at room temperature for 12 hrs. After the reaction was completed, the solution was evaporated under reduced pressure and the residue was triturated with ethanol to give crystals, which were collected by filtration and recrystallized from a mixture of ethanol and dimethyl formamide. 1.4g, 3 .33 mmol) and carbon disulfide (5 ml) in pyridine (15 ml) was refluxed for 10 hrs and then allowed to cool. The reaction mixture was triturated with water and acidified with dilute hydrochloric acid. The solid product was filtered, washed with water and air dried to give compound (8c 
4-(4-
(
4-(4-(2-Benzylidenehydrazinyl)-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (7b
